Skip to content

Study on the construction of drug risk analysis model of oseltamivir in pregnant population based on multi-level data mining

Study on the construction of drug risk analysis model of oseltamivir in pregnant population based on multi-level data mining

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000034920
Enrollment
Unknown
Registered
2020-07-24
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-07-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Influenza in pregnancy

Interventions

Sponsors

Beijing Maternity Hospital Affiliated to Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Pregnant people diagnosed with influenza or influenza related symptoms; 2. Subjects who use oseltamivir at any stage of pregnancy (from the last menstruation to delivery); 3. Pregnant women who voluntarily participated in the study and signed informed consent.

Exclusion criteria

Exclusion criteria: 1. The pregnant and lying in women themselves or their families can not accurately express the relevant registration information; 2. Prenatal diagnosis and other examinations may indicate possible pregnancy outcomes (such as the presence of congenital malformations); 3. Pregnant women with a history of tumor disease or diagnosed with tumor in this pregnancy; 4. The objects with congenital malformation.

Design outcomes

Primary

MeasureTime frame
Fetal Congenital Malformations;Adverse Drug Reaction;

Secondary

MeasureTime frame
Spontaneous abortion;preterm birth;Neonatal Complication;Labor Complication;Labor Complication;

Countries

China

Contacts

Public ContactRan Wang

Beijing Maternity Hospital Affiliated to Capital Medical University

wangran2233@126.com+86 18311103693

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026